Quantification of expression of antigens targeted by antibody-Based therapy in chronic lymphocytic leukemia

American Journal of Clinical Pathology

Volumn 140, Issue 6, 2013, Pages 813-818

  Tembhare, Prashant R ^a   Marti, Gerald ^b   Wiestner, Adrian ^c   Degheidy, Heba ^b   Farooqui, Mohammed ^c   Kreitman, Robert J ^d   Jasper, Gregory A ^a   Yuan, Constance M ^a   Liewehr, David ^e   Venzon, David ^e   Stetler Stevenson, Maryalice ^a  

^a Departments of Pathology and Laboratory Medicine   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Laboratory of Molecular Biology   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alemtuzumab; Antibody therapy; Chronic lymphocytic leukemia; Quantitative flow cytometry; Rituximab

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BL 22; CD20 ANTIGEN; CD22 ANTIGEN; CD52 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MOXETUMOMAB PASUDOTOX; ONCOTAC; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ALEMTUZUMAB; ANTIBODY THERAPY; CHRONIC LYMPHOCYTIC LEUKEMIA; QUANTITATIVE FLOW CYTOMETRY; RITUXIMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 84888214949     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPYFQ4XMGJD6TI     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. Ca Cancer J Clin. 2010;60:277-300
2. Plamer R, Denman AM. Malignancies induced by chlorambucil. Cancer Treat Rev. 1984;11:121-129
3. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165-2170
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-1174
5. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as singleagent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749-1755
6. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-5623
7. Alinari L, Lapalombella R, Andritsos L, et al. Alemtuzumab(Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene. 2007;26:3644-3653
8. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000;6:1476-1487
9. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase 1 trial of recombinant immunotoxin RFB4(dsFv)-PE38(BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23:6719-6729
10. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. ClinCancer Res. 2011;17:6398-6405
11. Kreitman RJ, Wilson WH, White JD, et al. Phase 1 trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB2) in patients with hematological malignancies. J Clin Oncol. 2000;18:1622-1636
12. Moreton P, Kennedy B, Lucas, G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia afteralemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971-2979
13. McLaughlin P, Grillo-Lopéz AJ, Link BK, et al. Rituximabchimeric anti-CD20 monoclonal antibody therapy for relapsedindolent lymphoma: half of patients respond to a four-dosetreatment program. J Clin Oncol. 1998;16:2825-2833
14. Dearden CM, E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol. 2006;19:795-810
15. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res. 1998;22:185-191
16. Jasper GA, Arun I, Venzon D, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytom B Clin Cytom. 2011;80B:83-90.
17. Wang L, Abbasi F, Jasper GA, et al. Variables in the quantification of CD4 in normals and hairy cell leukemiapatients. Cytometry B Clin Cytom. 2011;80B:51-56
18. Clinical and Laboratory Standards Institute. Document ILA24-A: Fluorescence Calibration and Quantitative Measurement of Fluorescence Intensity - Approved Guideline. Wayne, PA:Clinical and Laboratory Standards Institute; 2004
19. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on thegenetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol. 2008;141:36-40
20. Horvat M, Prevodnik VK, Lavrencak J, et al. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma. Oncol Rep. 2010;24:1101-1107
21. Pallis M, Syan J, Russell NH. Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34. Cytometry. 1999;37:308-313
22. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956-964
23. Ginaldi L, De Martinis, M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369
24. Huh YO, Keating MJ, Saffer HL, et al. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001;116:437-443
25. D'Arena G MP, Cascavilla N, Dell'Olio M, et al. Quantitativeflow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol.2000;64:275-281
26. Hsi E, Kopecky KJ, Appelbaum FR, et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol. 2003;120:1017-1025
27. Rossmann E, Lenkei R, Lundin J, et al. Performance of calibration standards for antigen quantitation with flow cytometry chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2007;72B:363-379
28. Wang L, Abbasi F, Gaigalas AK, et al. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells. Cytometry B Clin Cytom. 2006;70B:410-415
29. Lundin J, Kimby E, Bjorkholm M, et al. Phase 2 trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773
30. Wierda WG, Padmanabhan S, Chan GW, et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011;118:5126-5129
31. Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer. 2008;113:2110-2118